Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gastroenterology's Elusive Device Opportunity

This article was originally published in Start Up

Executive Summary

Gastroesophageal reflux disease and Barrett's Esophagus seem like obvious-and enormous-potential markets for interventional devices, but so far such devices have disappointed. In GERD, product malfunctions and recalls have underscored safety issues, while efficacy concerns and reimbursement delays have conspired to keep the enormous opportunity that GERD represents tantalizingly out of reach for many of the first-generation companies that were launched to tap into this market. Now, a small group of companies with hopes of a better approach are betting they've found the way to harness this most promising of device markets.

You may also be interested in...



EndoGastric Solutions Rewrites Playbook In Bid To Build GERD Business

Founded in 2001, EndoGastric Solutions Inc., a mature medical device company with $140 million in venture backing, hasn’t been able to secure a reliable source of reimbursement dollars for its EsophyX endoscopic treatment for GERD. Under new management, EGS is recommitting itself to collecting necessary clinical data and operating as a lean start-up as it makes its case for coverage and reimbursement with insurers.

Barrx Medical: Making A Case For Ablation

Barrx Medical set out seven years ago to compile enough clinical trial data to prove not only that ablation is a safe and effective way of treating Barrett's esophagus, but also that is cheaper than endoscopic surveillance. Its patience is beginning to pay off.

Barrx Medical: Making A Case For Ablation

Barrx Medical set out seven years ago to compile enough clinical trial data to prove not only that ablation is a safe and effective way of treating Barrett's esophagus, but also that is cheaper than endoscopic surveillance. Its patience is beginning to pay off.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT037385

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel